The relationship between serum Fetuin-A, Cystatin-C levels, and microalbuminuria in patients with metabolic syndrome

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 4, 2013, Pages 317-322

  Huddam, Bülent ^a   Azak, Alper ^a   Koçak, Gülay ^a   Bayraktar, Nilüfer ^b   Sezer, Siren ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Cystatin C; Fetuin A; Metabolic syndrome; Microalbuminuria

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CYSTATIN C; FETUIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CYSTATIN C BLOOD LEVEL; FEMALE; FETUIN A BLOOD LEVEL; HIP CIRCUMFERENCE; HUMAN; INSULIN RESISTANCE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RISK FACTOR; SOFT TISSUE CALCIFICATION; WAIST CIRCUMFERENCE;

CYSTATIN-C; FETUIN-A; METABOLIC SYNDROME; MICROALBUMINURIA;

ADULT; ALBUMINURIA; ALPHA-2-HS-GLYCOPROTEIN; BIOLOGICAL MARKERS; CYSTATIN C; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 84880372304     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21605     Document Type: Article

References (31)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
2. Sanders BH, Lubsch LM, West DS. Prevalence and treatment of metabolic syndrome in adolescents with type 2 diabetes. Ann Pharmacother 2006;40:1517-1521.
3. Earl S, Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004;27:2444-2449.
4. Bendriss L, Lebbaq A, Jallal H, Mrani S, Khatouri A. [Usefulness of microalbuminuria in the metabolic syndrome as a predictor of cardiovascular disease. Prospective study about 78 cases.]. Ann Cardiol Angeiol (Paris) 2012;61:15-19.
5. Michael H Davidson, MD. Management of dyslipidemia in patients with complicated metabolic synsdrome. Am J Cardiol 2005;96:22-25.
6. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS gylcoprotein during the inflammatory process: Evidence that alpha 2 HS2glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118-1129.
7. Westenfeld R, Jahnen-Dechentt W, Ketteler M. Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med 2007;17:124-128.
8. Ishibashi A, Ikeda Y, Ohguro T, et al. Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb 2010;17:925-933.
9. Xu Y, Xu M, Bi Y, et al. Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis 2011;216:180-186.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
11. Bakris GL. Microalbuminuria: Prognostic implications. Curr Opin Nephrol Hypertens 1996;5:219-223.
12. Varghese A, Deepa R, Rema M, Mohan V. Prevalence of microalbuminuria in type-II diabetes mellitus at a diabetes center in southern India. Postgrad Med J 2001;77:399-402.
13. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989;32:219-226.
14. Choi HS, Sung KC, Lee KB. The prevalence and risk factors of microalbuminuria in normoglycemic, normotensive adults. Clin Nephrol 2006;65:256-261.
15. Scaglione R, Ganguzza A, Corrao S, et al. Central obesity and hypertension: Pathophysiologic role of renal haemodynamics and function. Int J Obes Relat Metab Disord 1995;19:403-409.
16. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The insulin resistance atherosclerosis study. Diabetes 1998;47:793-800.
17. Zavaroni I, Bonini L, Gasparini P, et al. Dissociation between urinary albumin excretion and variables associated with insulin resistance in a healthy population. J Intern Med 1996;240:151-156.
18. Auberger P, Falquerho L, Contreres JO, et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 1989;58: 631-640.
19. Srinivas PR, Wagner AS, Reddy LV, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993;7:1445-1455.
20. Joachim H, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: Data from the Heart and Soul Study. Circulation 2006;113:1760-1767.
21. Roos M, Von Eynatten M, Heemann U, Rothenbacher D, Brenner H, Breitling LP. Serum fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease. Am J Cardiol 2010;105:1666-1672.
22. Stefan N, Hennige AM, Staiger H, et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006;29:853-857.
23. Vionnet N, Hani EH, Dupont S, et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: Evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000;67:1470-1480.
24. Hennige AM, Staiger H, Wicke C, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 2008;3:e1765.
25. Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005;96:946-951.
26. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008;118:1645-1656.
27. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010;21:406-412.
28. Li M, Xu M, Bi Y, et al. Association between higher serum fetuin-A concentrations and abnormal albuminuria in middle-aged and elderly chinese with normal glucose tolerance. Diabetes Care 2010;33:2462-2464.
29. Filler G, Bökenkamp A, Hofmann W, Bricon TL, Martinez-Bru C, Grubb A. Sistatin C as a marker of GFR-History, indications, and future research. Clin Biochem 2005;38:1-8.
30. Palatini P, Benetti E, Zanier A, et al. Cystatin C as predictor of microalbuminuria in the early stage of hypertension. Nephron Clin Pract 2009;113:309-331.
31. Jeon YK, Kim MR, Huh JE, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 2011;26:258-263.